Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 1
1999 1
2002 1
2009 1
2010 2
2011 2
2012 3
2015 1
2016 1
2018 1
2020 1
2021 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group. Kappos L, et al. N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089952 Free article. Clinical Trial.
The annualized relapse rate was 0.18 with 0.5 mg of fingolimod, 0.16 with 1.25 mg of fingolimod, and 0.40 with placebo (P<0.001 for either dose vs. placebo). Fingolimod at doses of 0.5 mg and 1.25 mg significantly reduced the risk of disability progression over the 24-m …
The annualized relapse rate was 0.18 with 0.5 mg of fingolimod, 0.16 with 1.25 mg of fingolimod, and 0.40 with placebo (P<0.001 fo …
Human papillomavirus in the etiology of head and neck carcinomas.
Michl P, Pazdera J, Prochazka M, Pink R, Stosova T. Michl P, et al. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010 Mar;154(1):9-12. doi: 10.5507/bp.2010.004. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010. PMID: 20445705 Free article. Review.
Efficacy and safety of eslicarbazepine acetate monotherapy in patients converting from carbamazepine.
Pazdera L, Sperling MR, Harvey JH, Sam MC, Strom LA, Blum D, Grinnell T, Cheng H. Pazdera L, et al. Epilepsia. 2018 Mar;59(3):704-714. doi: 10.1111/epi.14014. Epub 2018 Feb 16. Epilepsia. 2018. PMID: 29450890 Clinical Trial.
The higher risk of study exit in the subgroups that received CBZ (or any VGSCi) during baseline, versus other AEDs, was not statistically significant (hazard ratios were 1.49 for +CBZ vs -CBZ [P = .10] and 1.27 for +VGSCi vs. -VGSCi [P = .33]). Reductions in seizure …
The higher risk of study exit in the subgroups that received CBZ (or any VGSCi) during baseline, versus other AEDs, was not statistically si …
Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response.
Pazdera L, Cohen JM, Ning X, Campos VR, Yang R, Pozo-Rosich P. Pazdera L, et al. Cephalalgia. 2021 Sep;41(10):1075-1088. doi: 10.1177/03331024211008401. Epub 2021 May 14. Cephalalgia. 2021. PMID: 33990144 Free PMC article. Clinical Trial.
Changes from baseline in monthly average migraine days during 12 weeks were significantly greater with fremanezumab compared with placebo for patients with documented inadequate response to 2 classes (least-squares mean difference vs placebo [95% confidence interval]: quarterly, …
Changes from baseline in monthly average migraine days during 12 weeks were significantly greater with fremanezumab compared with placebo fo …
A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease.
Prins ND, Harrison JE, Chu HM, Blackburn K, Alam JJ, Scheltens P; REVERSE-SD Study Investigators. Prins ND, et al. Alzheimers Res Ther. 2021 May 27;13(1):106. doi: 10.1186/s13195-021-00843-2. Alzheimers Res Ther. 2021. PMID: 34044875 Free PMC article. Clinical Trial.
Secondary endpoints included change in Wechsler Memory Scale-IV (WMS) Immediate and Delayed Recall composites, CDR-SB, MMSE, and CSF biomarkers [total and phosphorylated tau (T-tau and p-tau(181)), Abeta(1-40), Abeta(1-42), neurogranin, and neurofilament light chain]. ...S …
Secondary endpoints included change in Wechsler Memory Scale-IV (WMS) Immediate and Delayed Recall composites, CDR-SB, MMSE, and CSF biomark …
Impact of veteran-led peer mentorship on posttraumatic stress disorder.
Franco Z, Ruffalo L, Curry B, Gollin-Graves M, Ahamed SI, Winstead O, Hooyer K, Pazdera M, Rein L, Lizarraga Mazaba J, Hossain MF, Stoffel V, Flower M, Madiraju P, Melka S, Berte K, Whittle J. Franco Z, et al. J Trauma Stress. 2024 Apr 18. doi: 10.1002/jts.23038. Online ahead of print. J Trauma Stress. 2024. PMID: 38635149
Week-by-week hazard of drop-out was lower with mentors 35 years old, aHR = 0.62, 95% CI [0.37, 1.05]. Unadjusted survival differed by mentor military branch, p = .028, but the small mentor sample reduced interpretability. ...
Week-by-week hazard of drop-out was lower with mentors 35 years old, aHR = 0.62, 95% CI [0.37, 1.05]. Unadjusted survival differed by mentor …
A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures.
Brodie MJ, Czapinski P, Pazdera L, Sander JW, Toledo M, Napoles M, Sahebkar F, Schreiber A; GWEP1330 Study Group. Brodie MJ, et al. Cannabis Cannabinoid Res. 2021 Dec;6(6):528-536. doi: 10.1089/can.2020.0075. Epub 2021 Feb 15. Cannabis Cannabinoid Res. 2021. PMID: 33998885 Free PMC article. Clinical Trial.
Results: Median baseline focal seizure frequencies were 17-18 per 28 days in both groups, and similar reductions in frequency were observed in the CBDV (40.5%) and placebo (37.7%) groups during the treatment period (treatment ratio [% reduction] CBDV/placebo: 0.95 [4.6]; confiden …
Results: Median baseline focal seizure frequencies were 17-18 per 28 days in both groups, and similar reductions in frequency were observed …
Symptoms and signs of posterior circulation ischemia in the new England medical center posterior circulation registry.
Searls DE, Pazdera L, Korbel E, Vysata O, Caplan LR. Searls DE, et al. Arch Neurol. 2012 Mar;69(3):346-51. doi: 10.1001/archneurol.2011.2083. Epub 2011 Nov 14. Arch Neurol. 2012. PMID: 22083796
Logistic regression analysis reveals that the clinical features dysphagia (P = .004; 95% CI, 1.8-24.4), nausea or vomiting (P = .002; 95% CI, 1.6-8.2), dizziness (P = .047; 95% CI, 1.0-5.4), and Horner syndrome (P = .001; 95% CI, 2.4-26.6) were positiv …
Logistic regression analysis reveals that the clinical features dysphagia (P = .004; 95% CI, 1.8-24.4), nausea or vomiting (P …
Identification of fat-cell enhancer regions in Drosophila melanogaster.
Miller JM, Oligino T, Pazdera M, López AJ, Hoshizaki DK. Miller JM, et al. Insect Mol Biol. 2002 Feb;11(1):67-77. doi: 10.1046/j.0962-1075.2001.00310.x. Insect Mol Biol. 2002. PMID: 11841504
., Ghosh, M. and Johnson, W. (1995) Identification of fat-cell enhancer activity in Drosophila melanogaster using P-element enhancer traps. Genome 38: 497-506; Riechmann, V., Rehorn, K.P., Reuter, R. and Leptin, M. (1998) The genetic control of the distinction betwe …
., Ghosh, M. and Johnson, W. (1995) Identification of fat-cell enhancer activity in Drosophila melanogaster using P-element enhancer …
19 results